Interpreting [18F]FDG-avid fractures after induction therapy in multiple myeloma: insights from the PET/CT sub-study of the Phase 3 GMMG-HD7 trial
Christos Sachpekidis(Democritus University of Thrace), H Goldschmidt(Heidelberg University), Marina Hajiyianni(Heidelberg University), Ekaterina Menis(Heidelberg University), Alexander Brobeil(Heidelberg University), Niels Weinhold(German Cancer Research Center), Annette Kopp‐Schneider(German Cancer Research Center), Sandra Sauer(Heidelberg University), Michael Hundemer(Heidelberg University), Markus Wennmann(German Cancer Research Center), Anna Jauch(Heidelberg University), J Hillengass(Roswell Park Comprehensive Cancer Center), Ulrike Dapunt(Heidelberg University), Marc S. Raab(Heidelberg University), Elias K. Mai(Heidelberg University), Lukas John(University of Hohenheim), Uta Bertsch(Heidelberg University), Antonia Dimitrakopoulou‐Strauss(German Cancer Research Center)
Cited by 0
Related Papers
Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
|Nature Communications|2017|418
Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single‐cell transcriptomics
|Nature Communications|2021|141
Encrypted federated learning for secure decentralized collaboration in cancer image analysis
|Medical Image Analysis|2023|88
Adjuvant Therapy with Edrecolomab versus Observation in Stage II Colon Cancer: A Multicenter Randomized Phase III Study*
|Oncology Research and Treatment|2005|64